Elevated inflammatory marker IL-6 associated with high levels of fatigue-ScienceDaily

Prostate cancer is one of the most common cancers among men in the United States. Hormone therapy is a treatment option for many patients. This type of therapy, also known as androgen deprivation therapy (ADT), lowers the levels of testosterone and other androgens in the body. Lowering androgen levels can slow the growth of prostate cancer cells and cause the tumor to shrink over time. However, patients undergoing ADT often experience higher levels of fatigue, depression, and cognitive impairment.

Researchers at the Mofit Cancer Center are investigating whether inflammation in the body, a side effect of ADT, contributes to these symptoms in patients with prostate cancer.In a new study published in the journal cancer, They identify specific inflammatory markers associated with increased malaise in this group of patients.

“This is the first study to investigate the association between inflammation and symptoms of fatigue, depression or cognitive impairment in prostate cancer patients undergoing ADT,” said the corresponding author and co-leader. One Dr. Heather Jim said. Health outcomes and behavioral programs at Mofit. “We believe that blockade of testosterone can increase inflammation in the body, so inflammation may also contribute to these symptoms.”

In this study, the research team evaluated two groups of men. A control group of healthy men of the same age as prostate cancer patients who started ADT. Men were reassessed at the start of the study and at 6 and 12 months. Evaluations included fatigue, depression, other neuropsychological tests, and blood draws. Blood tests show circulatory markers of inflammation, especially interleukin-1 receptor antagonist (IL-1RA), interleukin-6 (IL-6), soluble tumor necrosis factor receptor-2 (sTNF-R2) and C reaction. Sex protein (CRP).

The groups did not differ at baseline, but the researchers noticed a significant increase in malaise and depressive symptoms in ADT patients over a 12-month period. They also saw an increase in one inflammatory marker, IL-6, in this group of patients.

“Interleukin-6 is an pro-inflammatory cytokine that is often associated with sleep disorders and thus fatigue,” said Dr. Aasha Hoogland, Principal Research Author and Applied Research Scientist for Mofit’s Health Outcomes and Behavioral Program. I have. “Studies have shown that testosterone can suppress the effects of IL-6, but ADT limits testosterone production in the body, so elevated levels may be seen in this group of patients. . “

Researchers say additional research is needed to see if interventions such as anti-inflammatory drugs and exercise can help alleviate fatigue and depressive symptoms in ADT patients.

This study was supported by the National Institutes of Health (R01CA132803 and P30CA076292) and the Miles for Moffitt Milestone Award.

Story source:

Materials provided by H. Remofit Cancer Center & Laboratory.. Note: The content can be edited in style and length.

Back to top button